The role of prostatic specific antigen in early diagnosis of prostate cancer: retrospective analysis of data from the Polyclinic 1 North Kazakhstan region

This study is of an evaluative nature and is based on a retrospective analysis of data from 18 patients of the oncological office of the City Polyclinic No. 1 of the North Kazakhstan region (North Kazakhstan region). PSA levels were compared in patients with various histological diagnoses, including adenocarcinoma, microcarcinoma, benign hyperplasia and inflammatory processes.

High PSA levels (> 25 ng/mL) were expected to be a reliable indicator of malignancy, demonstrating a significant difference between gallbladder carcinoma patients and benign changes.

Moderate PSA values (4-10 ng/mL) were to include both patients with benign processes and those with precancerous conditions.

Low PSA levels (< 4 ng/mL) were expected in patients without evidence of malignancy, which could serve as an additional criterion for exclusion of oncology.

The findings confirmed the importance of PSA as a marker for gallbladder carcinoma diagnosis, but also demonstrated its limited specificity. To improve the accuracy of diagnostics, it is recommended to use additional parameters (the ratio of free and bound PSA, the density of the PSA, the rate of change in the PSA level), as well as apply modern methods of visualization and molecular diagnostics.

1. Klinicheskaya znachimost' PSA-associirovannyh testov v diagnostike i monitoringe raka predstatel'noj zhelezy // Onkologiya. Zhurnal im. P.A. Gercena. - 2018. - №1. - S. 55-62.

2. Prostat-specificheskij antigen kak marker zabolevanij predstatel'noj zhelezy i mishen' dlya lekarstvennyh preparatov: obzor literatury // Klinicheskaya onkologiya. - 2019. - T. 25, №3. - S. 460-464.

3. Yin L., Hu Q., Hartman M., Xu L., Jin Y., Li Y., et al. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health. 2022 Mar 3; 10:811044. doi: m.3389/fpubh.2022.8n044. PMID: 35252092; PMCID: PMC8888523.

4. Kurzanov A.N., Strygina E.A., Medvedev V.L. Diagnosticheskie i prognosticheskie markery raka predstatel'noj zhelezy // Sovremennye problemy nauki i obrazovaniya. - 2016. - №2.

5. Kosarev E.I., Nesterov S.N., Hanaliev B.V. Ispol'zovanie onkomarkerov v urologicheskoj praktike: PSA kak naibolee chasto ispol'zuemyj marker v differencial'noj diagnostike u onkourologov // Vestnik Nacional'nogo mediko-hirurgicheskogo Centra im. N.I. Pirogova. - 2018, t. 13, №4.

6. D.Yu. Pushkar', A.V. Govorov, A.V. Sidorenkov, A.O. Vasil'ev Specificheskij antigen raka predstatel'noj zhelezy 3 (rsa3) - metodicheskie rekomendacii № 66 © Kollektiv avtorov, © ID «ABVpress». - Moskva, 2018.

7. Bulychkin P.V., Tkachev S.I., Matveev V.B., Nazarenko A.V. Prostaticheskij specificheskij antigen - prediktor effektivnosti spasitel'noj luchevoj terapii bol'nyh s recidivami raka predstatel'noj zhelezy posle radikal'noj prostatektomii. Onkourologiya 2019;15(2):66-72

8. Cherkasova Zh.R., Curkan S.A., Prostyakova A.I., Boroda A.M., Rozhkov A.A., Pirogova Yu.N., Nikitina N.M., Sekacheva M.I. Vozmozhnost' klinicheskogo primeneniya rakovogo antigena SA-62 pri povyshennom urovne prostat- specificheskogo antigena dlya differenciaTnoj diagnostiki raka predstatel'noj zhelezy i dobrokachestvennoj giperplazii predstatel'noj zhelezy. Issledovaniya i praktika v medicine. 2023; 10(1):10-26. https://doi.org/rn.17709/24m-1893-2023-10-1-1, EDN: JVPCQC

9. Sidorenkov A.V., Govorov A.V., Sadchenko A.V., Pushkar' D.Yu. Diagnosticheskaya znachimost' [-2] proPSA i PHI (obzor literatury). Onkourologiya. 2014;10(4):87-95. https://doi.org/10.17650/1726-9776-2014-10-4-87-95

10. Rak predstatel'noj zhelezy: posobie dlya pacientov / A.V. Govorov, A.O. Vasil'ev, D.Yu. Pushkar'. - M.: GBU «NIIOZMM DZM», 2023. - 16 s.: il.

11. Nosov D.A., Volkova M.I., Gladkov O.A., Karabina E.V., Krylov V.V., Matveev V.B. i soavt. Prakticheskie rekomendacii po lekarstvennomu lecheniju raka predstatel'noj zhelezy. Prakticheskie rekomendacii RUSSCO, chast' 1. Zlokachestvennye opuholi, 2023 (tom 13), #3s2, str. 640-660.